Hypertrophic Cardiomyopathy: New Evidence, Updated Guidelines to Support Optimal Management

Hypertrophic Cardiomyopathy: New Evidence, Updated Guidelines to Support Optimal Management is organized by AcademicCME.

Program Dates: May 8, 2024 - May 7, 2025

Description:
Hypertrophic cardiomyopathy (HCM) affects 1 in 200-500 people and leads to hyper-contractility of the ventricles of the heart. HCM is the leading cause of sudden death in young adults, often taking an insidious clinical course. Early detection may be beneficial for prevention of significant morbidity and mortality in high?risk patients, and specialty-specific tools to aid in that early diagnosis are needed. Unfortunately, the clinical and genetic complexity of HCM and its manifold molecular mechanisms have hindered the development of effective treatment options. Directly manipulating the power output of cardiac muscle at the molecular level via a targeted small-molecule inhibitor of myosin would abrogate the elevated contractile force of the HCM heart and potentially improve symptoms and alter the course of disease progression. A signal advance in the management of HCM has been achieved with the first regulatory approval of such a myosin inhibitor. We have now entered a new era of HCM management, and our global expert faculty in this program will educate learners on the pathophysiology of the disease, the latest diagnostic imaging techniques, and optimal treatment as per the 2023 ESC Cardiomyopathy Management Guidelines. 

Learning Objectives:

• An improved understanding of the prevalence, pathophysiology, unmet patient needs, and natural course of HCM
• Improved confidence and competence in diagnostic skill for recognizing HC
• A clear understanding of the differences between symptom management and pathophysiology-targeted treatment for patients with HCM
• Practice-pertinent awareness of the most recent clinical data on the efficacy and safety of CMIs in the management of HCM
• Familiarity with the most current specialty society guidelines addressing the management of HCM.